CA2860369A1 - Biomarqueur predictif pour le traitement du cancer avec des anticorps actives par adcc - Google Patents

Biomarqueur predictif pour le traitement du cancer avec des anticorps actives par adcc Download PDF

Info

Publication number
CA2860369A1
CA2860369A1 CA2860369A CA2860369A CA2860369A1 CA 2860369 A1 CA2860369 A1 CA 2860369A1 CA 2860369 A CA2860369 A CA 2860369A CA 2860369 A CA2860369 A CA 2860369A CA 2860369 A1 CA2860369 A1 CA 2860369A1
Authority
CA
Canada
Prior art keywords
level
antibody
adcc
treatment
cell infiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2860369A
Other languages
English (en)
Inventor
Christian Gerdes
Claude GIMMI
Simon HOLLINGSWORTH
Luigi MANENTI
Ruediger Rueger
Pablo Umana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Glycart AG
Original Assignee
Roche Glycart AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart AG filed Critical Roche Glycart AG
Publication of CA2860369A1 publication Critical patent/CA2860369A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2860369A 2012-03-02 2012-03-02 Biomarqueur predictif pour le traitement du cancer avec des anticorps actives par adcc Abandoned CA2860369A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/053600 WO2013127465A1 (fr) 2012-03-02 2012-03-02 Biomarqueur prédictif pour le traitement du cancer avec des anticorps activés par adcc

Publications (1)

Publication Number Publication Date
CA2860369A1 true CA2860369A1 (fr) 2013-09-06

Family

ID=45814493

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2860369A Abandoned CA2860369A1 (fr) 2012-03-02 2012-03-02 Biomarqueur predictif pour le traitement du cancer avec des anticorps actives par adcc

Country Status (8)

Country Link
JP (1) JP2015511702A (fr)
KR (1) KR20140130455A (fr)
AU (1) AU2012371260A1 (fr)
BR (1) BR112014018374A8 (fr)
CA (1) CA2860369A1 (fr)
MX (1) MX2014010379A (fr)
RU (1) RU2014138586A (fr)
WO (1) WO2013127465A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2014114595A1 (fr) 2013-01-23 2014-07-31 Roche Glycart Ag Biomarqueur prédictif pour traitement anticancéreux au moyen d'anticorps à activité adcc accrue
JP6827319B2 (ja) * 2014-05-08 2021-02-10 中外製薬株式会社 Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7096667B2 (ja) * 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0368684B2 (fr) 1988-11-11 2004-09-29 Medical Research Council Clonage de séquences d'immunoglobulines de domaines variables.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP2248892B1 (fr) 2003-01-22 2015-04-22 Roche Glycart AG Constructions à fusion et utilisation associée pour produire des anticorps avec un récepteur FC liant l'affinité et fonction effectrice
PL1871805T3 (pl) 2005-02-07 2020-03-31 Roche Glycart Ag Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
DE602007013068D1 (de) * 2006-09-13 2011-04-21 Glycode Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper
US20100247484A1 (en) * 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
WO2011084333A1 (fr) * 2009-12-16 2011-07-14 Hitachi Chemical Co., Ltd. Procédé pour caractériser la fonction immunitaire de l'hôte par induction ex vivo de marqueurs immunitaires offensifs et défensifs

Also Published As

Publication number Publication date
AU2012371260A8 (en) 2014-09-18
KR20140130455A (ko) 2014-11-10
WO2013127465A1 (fr) 2013-09-06
BR112014018374A2 (fr) 2017-06-20
JP2015511702A (ja) 2015-04-20
BR112014018374A8 (pt) 2017-07-11
AU2012371260A1 (en) 2014-07-10
MX2014010379A (es) 2015-05-15
RU2014138586A (ru) 2016-04-20

Similar Documents

Publication Publication Date Title
US20250066501A1 (en) Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
AU2016281717B2 (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38
CN103119064B (zh) Fab糖基化抗体
CN111060687A (zh) 用于向gpc3靶向治疗剂疗法有效的患者施予的gpc3靶向治疗剂
JP6857138B2 (ja) Ａｘｌタンパク質に結合する抗体
CA2860369A1 (fr) Biomarqueur predictif pour le traitement du cancer avec des anticorps actives par adcc
JP2022081519A (ja) Ｍｕｃ１６陽性癌治療の応答性を評価するためのヒト精巣上体タンパク質４（ｈｅ４）の使用
KR20240105455A (ko) 클라우딘 18.2 길항제와 pd-1/pd-l1 축 억제제의 조합 요법
TW202304526A (zh) Ｎｋ細胞接合劑相關之不良反應之預防或減輕
JP7072703B2 (ja) Ａｘｌタンパク質に結合する抗体
US20130195854A1 (en) Predictive biomarker for cancer treatment with adcc-enhanced antibodies
US9360481B2 (en) Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
CN111108123A (zh) 癌症相关的免疫抑制抑制剂
US20130273032A1 (en) Predictive biomarker for cancer treatment with adcc-enhanced antibodies
US20190218302A1 (en) Anti-cancer combination treatment
KR20250158056A (ko) 이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
WO2025064690A1 (fr) Anticorps à haute affinité reconnaissant le noyau 2 o-glycanes d'antigène muc5ac variant, compositions le contenant et utilisations associées
EP3557260B1 (fr) Médicament de ciblage gpc3 administré à un patient en réponse à une thérapie médicamenteuse de ciblage gpc3
HK1254942B (en) Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
HK40019410A (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170302